Keyword: Revlimid

Celgene is extracting volume-driven sales growth as the entire industry has come under scrutiny for its pricing.

Celgene ended a losing streak Monday with a Revlimid trial win, and one analyst thinks more rosy pipeline events could follow soon.

Though Trump convinced Pfizer to delay its planned price increases, Celgene, Roche and Novo have gone through with their own increases in July.

Celgene CEO Mark Alles pledged to control price increases, but it's unclear whether the vow applies to cancer blockbuster Revlimid.

Blockbusters Humira and Keytruda will lead 2024 sales, according to an EvaluatePharma report, joined by new Sanofi launch Dupixent.

Celgene's business development chief George Golumbeski left the company in April as Celgene struggles to recover from months of setbacks.

FDA Commissioner Scott Gottlieb has turned to an unusual tactic to tackle drug pricing through generics competition.

Higher net prices for Humira and Revlimid fueled growth in the fourth quarter for AbbVie and Celgene, respectively, a report found.

The departure of Celgene COO Scott Smith wasn't entirely surprising, given recent setbacks, including a delayed FDA decision on the company's MS candidate ozanimod.

Celgene’s stock has taken a beating thanks to a string of bad news. But the situation isn’t as dire as its share price suggests, one analyst insists.